AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3318971
Drug: Almitrine bismesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bismesylate (100-200 mg per day orally in two divided doses)
Trial: 24994597
Drug: Melacine vaccine
RxNorm normalized name: melamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melacine vaccine for 2 years
Trial: 24994597
Drug: Melacine vaccine
RxNorm normalized name: melamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melacine vaccine in HLA-A2 and/or HLA-Cw3 serotype patients (n = 178)
Trial: 17251232
Drug: Standard bronchodilator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard bronchodilator treatment (SBDT) only
Trial: 10216540
Drug: PGE1 infusion
RxNorm normalized name: PGE1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGE1 infusion started at 0.05 microgram/kg/min, decreased to 0.005-0.01 microgram/kg/min for maintenance.
Trial: 10216540
Drug: PGE1 infusion
RxNorm normalized name: PGE1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGE1 infusion for Group IV (left ventricular volume improvement).
Trial: 22490713
Drug: High-dose tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tirofiban
Trial: 22944274
Drug: Normal-dose tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-dose tirofiban
Trial: 9234663
Drug: Stepwise dobutamine-infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepwise dobutamine-infusion protocol (10-40 microg/kg/min, 3-min intervals)
Trial: 9234663
Drug: Continuous dobutamine-infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous dobutamine-infusion protocol (10 microg/kg/min for 12 min)
Trial: 9234663
Drug: Stepwise dobutamine-infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepwise dobutamine-infusion protocol
Trial: 7900237
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with low-dose IL-2 (3 million IU/day subcutaneously for 6 days/week for 4 weeks) plus melatonin (40 mg/day orally, starting 7 days before IL-2)
Trial: 7900237
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with low-dose IL-2 plus MLT
Trial: 31621254
Drug: Auricular acupuncture
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular acupuncture combined with dydrogesterone (10 mg orally twice a day until 12 weeks of pregnancy)
Trial: 22964169
Drug: Sorafenib 400mg
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib 400mg twice daily plus subcutaneous IFN, 9 million units (MU) three times a week (Arm A)
Trial: 22964169
Drug: Sorafenib 400mg
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib 400mg twice daily plus subcutaneous IFN, 3 MU five times a week (Arm B)
Trial: 21221804
Drug: Daily CIFN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily CIFN (15 mcg/day SQ) and RBV (1‐1.2 g/d PO) for 52 weeks (group A, n = 33)
Trial: 21221804
Drug: Daily CIFN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily CIFN (15 mcg/day SQ) and RBV (1‐1.2 g/d PO) for 52-72 weeks (group B, n = 31)
Trial: 21221804
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (n=64)
Trial: 18828055
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose ceftriaxone
Trial: 18828055
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ampiclox, gentamicin, and metronidazole
Trial: 23946704
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg modafinil once daily for 4 weeks
Trial: 23946704
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 4 weeks
Trial: 21251795
Drug: Matched-placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched-placebo administration
Trial: 21251795
Drug: Immediate-release opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release opioid administration in high PCS scorers
Trial: 21251795
Drug: Matched-placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched-placebo administration in high PCS scorers
Trial: 21251795
Drug: Immediate-release opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release opioid administration in low PCS scorers
Trial: 19091796
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A (240 mg in 4 doses)
Trial: 15093907
Drug: High-dose radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose radiotherapy (64.8 Gy in 36 fractions)
Trial: 15093907
Drug: Low-dose radiotherapy
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose radiotherapy (50.4 Gy in 28 fractions)
Trial: 28130659
Drug: Pitavastatin 1-4
RxNorm normalized name: pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin 1-4 mg once daily
Trial: 21289249
Drug: D(2) dosing
RxNorm normalized name: Vitamin D-2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D(2) dosing
Trial: 21289249
Drug: D(3) dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D(3) dosing
Trial: 17873686
Drug: XR-NTX 190
RxNorm normalized name: metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: XR-NTX 190 mg
Trial: 30587520
Drug: Ventro-oral thalamotomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventro-oral thalamotomy
Trial: 24861134
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of warfarin on Day 1
Trial: 18311852
Drug: Established treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Established treatment
Trial: 17198588
Drug: Standardized Tertiary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized Tertiary Rehabilitation (STR) including physical therapy and occupational therapy (OT)
Trial: 17198588
Drug: Routine intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine intervention of internal medicine (Control)
Trial: 24802206
Drug: Intensified Conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified Conventional Treatment (ICT)
Trial: 4089188
Drug: Sulpiride 10
RxNorm normalized name: sulpiride 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride 10 mg
Trial: 4089188
Drug: Sulpiride 20
RxNorm normalized name: sulpiride 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride 20 mg
Trial: 4089188
Drug: Arginine HCl
RxNorm normalized name: arginine HCl
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine HCl infusion (0.33G/kg)
Trial: 24074713
Drug: High-dose aspartate-ornithine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aspartate-ornithine granules (6 g bid po)
Trial: 24074713
Drug: Low-dose aspartate-ornithine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspartate-ornithine granules (3 g bid po)
Trial: 21437745
Drug: Usual oral
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual oral information plus an information leaflet about SSI (group O/L)
Trial: 21437745
Drug: Usual oral
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual oral information alone (group O)
Trial: 18534421
Drug: Portable, continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Portable, continuous enhanced circulation therapy (CECT) + low-molecular-weight heparin (LMWH)
Trial: 12119640
Drug: Greater initial
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Greater initial weight loss induced without changes in lifestyle (e.g. liquid formula diets or anorectic drugs)
Trial: 12119640
Drug: 1-2 years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-2 years integrated weight maintenance programme consisting of lifestyle interventions (dietary change, nutritional education, behaviour therapy, increased physical activity)
Trial: 8682976
Drug: Amitriptyline (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (150 mg/day) + sleep deprivation (6 treatments at 4-5 day intervals)
Trial: 22987495
Drug: Cognitive-behaviour therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behaviour therapy
Trial: 25341682
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (regular medical treatment)
Trial: 24135530
Drug: MCI-186 (edaravone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCI-186 (edaravone) with a loading dose of 0.08 mg/kg + 0.2 mg/kg/h infusion
Trial: 24135530
Drug: MCI-186 (edaravone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCI-186 (edaravone) with a loading dose of 0.16 mg/kg + 0.4 mg/kg/h infusion
Trial: 16980316
Drug: Acupuncture (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (10 individualised treatments)
Trial: 8433884
Drug: Glucose with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose with amino acids (1.5 g.kg‐1.d‐1) i.v.
Trial: 3127815
Drug: doxycycline 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxycycline 0.1 g x 2
Trial: 3127815
Drug: demethylchlortetracycline (DMCT)
RxNorm normalized name: Demethylchlortetracyclin
DrugBank: Demeclocycline (DB00618)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: demethylchlortetracycline (DMCT) 0.3 g x 2
Trial: 3127815
Drug: lymecycline 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lymecycline 0.6 g x 2
Trial: 18394765
Drug: LJEV administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LJEV administered at age of 8 months and MV at 9 months (Group 1)
Trial: 20852004
Drug: Pantoprazole 20
RxNorm normalized name: pantoprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 20 mg once daily
Trial: 8561641
Drug: CP-treated group
RxNorm normalized name: methylcellulose (1500 CPS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-treated group (St. Thomas' Hospital cardioplegic solution No. 1 plus CP 10 mmol/L)
Trial: 8561641
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (St. Thomas' Hospital cardioplegic solution No. 1)
Trial: 1871547
Drug: Bedtime UDCA
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime UDCA 7 mg/kg/day
Trial: 1871547
Drug: Mealtime UDCA
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mealtime UDCA 10 mg/kg/day
Trial: 1871547
Drug: Bedtime UDCA
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime UDCA (average minimum effective dose) 8.4 mg/kg/day
Trial: 1871547
Drug: Repeated-release tablet
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated-release tablet formulation of UDCA
Trial: 6221200
Drug: THIP (4,5,6,7‐tetrahydroisoxazolo‐[5,4,‐c]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THIP (4,5,6,7‐tetrahydroisoxazolo‐[5,4,‐c] pyridin‐3‐ol) administered orally for 2 weeks
Trial: 6221200
Drug: High-dose THIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose THIP therapy
Trial: 30059193
Drug: AAA tablet
RxNorm normalized name: JNJ-63839880-AAA
DrugBank: MVA-mBN226B (DB17780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAA tablet
Trial: 30059193
Drug: NXA tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NXA tablet
Trial: 6885201
Drug: Both tablet
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both tablet formulations
Trial: 18580553
Drug: Continuation pharmacotherapy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation pharmacotherapy
Trial: 21974759
Drug: valsartan/HCTZ 160/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valsartan/HCTZ 160/12.5 mg
Trial: 3382038
Drug: Edrophonium 0.67
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.67 mg/kg with atropine doses ranging from 0.0125 to 0.0215 mg/kg (group A, n = 37)
Trial: 3382038
Drug: Edrophonium 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 1.0 mg/kg with atropine doses ranging from 0.02 to 0.04 mg/kg (group B, n = 35)
Trial: 26712409
Drug: Population pharmacokinetic
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Population pharmacokinetic model for morphine after oral administration of DTO
Trial: 20860867
Drug: Cognitive Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Enhancement Therapy (CET)
Trial: 12556006
Drug: Salmeterol 50
RxNorm normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 50 mcg twice daily
Trial: 12544410
Drug: Nelfinavir (part
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nelfinavir (part of dual nucleoside reverse transcriptase inhibitor therapy)
Trial: 12544410
Drug: Full adherence
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full adherence to prescribed medication
Trial: 8898461
Drug: Integrated control
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated control measures including health education, sanitation, environmental management, and chemotherapy
Trial: 23882088
Drug: Ibuprofen, Acetaminophen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen, Acetaminophen, Placebo
Trial: 20581724
Drug: Zolpidem 10
RxNorm normalized name: zolpidem 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 10 mg for 5 weeks
Trial: 18076221
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (n = 25) - Stepwise periodized resistance exercise program + additional rotational and full-body medicine ball exercises, 3 days/week for 12 weeks
Trial: 16219016
Drug: Once-daily gliclazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily gliclazide MR
Trial: 16219016
Drug: Twice-daily glibenclamide
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily glibenclamide
Trial: 2502074
Drug: Sunfural S
RxNorm normalized name: S-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunfural S (new oral form)
Trial: 2502074
Drug: Sunfural Rectal
RxNorm normalized name: Furfural
DrugBank: Furfural (DB16856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunfural Rectal Capsules (new soft-capsule suppository form)
Trial: 2502074
Drug: existing drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: existing drugs
Trial: 30359764
Drug: Pre-emptive analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-emptive analgesia with paracetamol (P), ketorolac (K), and pregabalin (PR) administered 4 hours before surgery
Trial: 25885548
Drug: Nutritional intervention
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional intervention with a neurotrophic dietary supplement
Trial: 19744717
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin (6 biannual mass treatments)
Trial: 29045995
Drug: Carbohydrate‐electrolyte solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate‐electrolyte solution (CES)
Trial: 15551195
Drug: mCPP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mCPP infusion (serotonin agonist)
Trial: 24621122
Drug: Formulation containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation containing 10 mg lutein, 10 mg meso-zeaxanthin, 2 mg zeaxanthin, 500 mg vitamin C, 400 IU vitamin E, 25 mg zinc, and 2 mg copper (Intervention A; Trial 2)
Trial: 24621122
Drug: Formulation containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation containing 10 mg lutein and 2 mg zeaxanthin, 500 mg vitamin C, 400 IU vitamin E, 25 mg zinc, and 2 mg copper (Intervention B; Trial 2)
Trial: 17405895
Drug: Glutamine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (15 g twice a day for seven consecutive days every 2 weeks starting on the day of oxaliplatin infusion)
Trial: 1335221
Drug: Intravenous diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diazepam (four logarithmically increasing doses)
Trial: 6145734
Drug: Intravenous diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diazepam
Trial: 28418482
Drug: Dexamethasone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (10 mg, single oral dose)
Trial: 25613634
Drug: Yiqi Houxue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiqi Houxue Bushen Decoction (treatment group)
Trial: 17156466
Drug: Pre-pregnancy intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-pregnancy intervention provided by midwives, including discussions on social, health or lifestyle problems, preparation and timing for pregnancy, family history, rubella immunisation, referrals for health problems, and a reminder card.
Trial: 24879552
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy exercise program
Trial: 18794207
Drug: Olanzapine (2.5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (2.5-20 mg/day)
Trial: 18594050
Drug: Candesartan (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (6 months treatment)
Trial: 10189126
Drug: Concurrent 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent 5-fluorouracil (5-FU)
Trial: 7485297
Drug: Hospital-compounded formulation
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital-compounded formulation of 0.5 mg of prostaglandin E2 gel
Trial: 2218419
Drug: Ofloxacin 200
RxNorm normalized name: ofloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 200 mg b.i.d. for seven days
Trial: 2218419
Drug: Erythromycin 500
RxNorm normalized name: erythromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 500 mg b.i.d. for seven days
Trial: 31477061
Drug: Standard model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard model of family psychoeducation (SM-FPE) plus treatment as usual (TAU)
Trial: 26867542
Drug: Continuing acute
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing acute noninvasive ventilation as a long-term therapy
Trial: 11377645
Drug: Interferon beta‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta‐1a 22 microg subcutaneously once weekly for 2 years
Trial: 9555794
Drug: Acidified nitrite
RxNorm normalized name: Nitrite
DrugBank: Nitrite (DB12529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acidified nitrite cream (3% salicylic acid in aqueous cream and 3% nitrite in aqueous cream) applied twice daily for 4 weeks
Trial: 27528067
Drug: Autonomic blockade
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autonomic blockade (trimethaphan 4 mg/min IV)
Trial: 24734184
Drug: 400 mcg
RxNorm normalized name: Biotin 400 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mcg oral misoprostol (as two tablets) and 2 mL normal saline in 1000 mL Ringer's solution
Trial: 24734184
Drug: 20 IU
RxNorm normalized name: Calcium/Phosphorus/Vitamin D 105 MG-81 MG-120 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 IU of oxytocin in 1000 mL Ringer's solution and two placebo tablets
Trial: 20456355
Drug: Vorinostat (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorinostat (400 mg TID for 3 days) in combination with idarubicin
Trial: 18593524
Drug: VPA DR
RxNorm normalized name: Dr. Numb
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VPA DR soft gelatin capsule (500 mg), non-fasting
Trial: 16202734
Drug: Intra-amniotic PGF2alpha
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-amniotic PGF2alpha (carboprost 1.5 mg)
Trial: 9182114
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg bd for three days
Trial: 9182114
Drug: Norfloxacin 800
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norfloxacin 800 mg as a single dose
Trial: 9182114
Drug: Multidose norfloxacin
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multidose norfloxacin treatment